BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 3926310)

  • 1. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of advanced ovarian cancer].
    de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
    Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
    Piver MS; Lele S; Barlow JJ
    Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 7. Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Carlson JA; Day TG; Botts B; Masterson BJ
    Gynecol Oncol; 1985 Oct; 22(2):189-94. PubMed ID: 3932141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy for advanced ovarian cancer: a prospective randomized trial comparing hexamethylmelamine and cyclophosphamide to doxorubicin and cyclophosphamide.
    Schwartz PE; Lawrence R; Katz M
    Cancer Treat Rep; 1981; 65(1-2):137-41. PubMed ID: 6261948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
    Edmonson JH; McCormack GW; Fleming TR; Cullinan SA; Krook JE; Malkasian GD; Podratz KC; Mailliard JA; Jefferies JA; Barlow JF
    Cancer Treat Rep; 1985 Nov; 69(11):1243-8. PubMed ID: 3937598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
    van der Hoop RG; van der Burg ME; ten Bokkel Huinink WW; van Houwelingen C; Neijt JP
    Cancer; 1990 Oct; 66(8):1697-702. PubMed ID: 2119878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
    Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
    Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
    Bruckner HW; Cohen CJ; Feuer E; Holland JF
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Mäenpää J; Kangas L; Grönroos M
    Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy.
    Bruckner HW; Cohen CJ; Feuer E; Wallach RC; Kabakow B; Holland JF
    Obstet Gynecol; 1987 Jan; 69(1):114-20. PubMed ID: 3099235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.
    Hartenbach EM; Harris LS; Bailey HH; Grosen EA; Larrison E; Chen D; Twiggs LB; Schink JC
    Cancer J Sci Am; 1999; 5(6):348-55. PubMed ID: 10606476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of combination chemotherapy programs in advanced adenocarcinoma-large cell carcinoma of the lung: a North Central Cancer Treatment Group study.
    Krook JE; Fleming TR; Eagan RT; Cullinan S; Pfeifle D; Elliott T; Etzell P
    Cancer Treat Rep; 1984 Mar; 68(3):493-8. PubMed ID: 6322987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chemotherapy of epithelial ovarian carcinoma].
    Bruntsch U; Gallmeier WM
    MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.